AJP - Gastrointestinal and Liver Physiology, Vol 258, Issue 4 648-G651, Copyright © 1990 by American Physiological Society

ARTICLES

A71378: a CCK agonist with high potency and selectivity for CCK-A receptors

C. W. Lin, M. W. Holladay, D. G. Witte, T. R. Miller, C. A. Wolfram, B. R. Bianchi, M. J. Bennett and A. M. Nadzan
Neuroscience Research Division, Abbott Laboratories, Abbott Park, Illinois 60064.

Receptors for the brain and gut peptide cholecystokinin (CCK) have been classified into two classes, CCK-A and CCK-B. To date, peptide analogues with selectivity for the CCK-B receptors have been identified, and selective antagonists for CCK-A and CCK-B receptors have been reported as well; until now, there have been no reports of highly selective CCK-A agonists. Herein we describe the properties of A71378 [desamino-Try(SO3H)-Nle-Gly-Trp-Nle-(N-methyl)Asp-Phe-NH2], a highly selective CCK-A receptor ligand. Characterization of A71378 was carried out in the guinea pig pancreas, cortex, gastric gland, and ileum, as well as in NCI-H345 cells. The IC50 values of A71378 for the pancreatic CCK-A, cortical CCK-B, and gastrin receptor were 0.4 nM, 300 nM, and 1,200 nM, respectively. A71378 proved to be a potent agonist in eliciting pancreatic amylase secretion (EC50 = 0.16 nM) and ileal muscle contraction (EC50 = 3.7 nM). In contrast, A71378 was relatively weak (EC50 = 600 nM) in mobilizing intracellular calcium from NCI-H345 cells, which express CCK-B/gastrin receptors. The high potency and selectivity of A71378 for the CCK-A over CCK-B and gastrin receptors is unprecedented among CCK peptides. Studies on CCK-7 analogues indicate that N-methylation of the Asp residue is responsible for the observed selectivity for CCK-A receptors. This discovery of a selective CCK-A agonist should prove valuable for studies aimed at understanding the physiological roles of CCK-A receptors in the brain and periphery.

This article has been cited by other articles:

				E. Bignon, A. Bachy, R. Boigegrain, R. Brodin, M. Cottineau, D. Gully, J.-M. Herbert, P. Keane, C. Labie, J.-C. Molimard, et al. SR146131: A New Potent, Orally Active, and Selective Nonpeptide Cholecystokinin Subtype 1 Receptor Agonist. I: In Vitro Studies J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 742 - 751. [Abstract] [Full Text]